Amylyx Pharmaceuticals Inc.
Clinical trials sponsored by Amylyx Pharmaceuticals Inc., explained in plain language.
A biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including ALS and Alzheimer's disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New ALS drug targets nerve damage in early human trial Results expected Feb 2027 (estimated) May already have reported ↗
-
New hope for Post-Surgery sugar crashes: avexitide trial underway
Disease control OngoingThis study tests a drug called avexitide in 75 adults who have dangerous low blood sugar episodes after gastric bypass surgery. Participants receive either the drug or a placebo for 16 weeks to see if it reduces severe sugar crashes. The goal is to control this long-term conditio…
Phase 3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Hope for rare wolfram syndrome: drug aims to slow diabetes progression
Disease control OngoingThis study tests an experimental drug called AMX0035 in 12 adults with Wolfram syndrome, a rare genetic disorder that causes diabetes and vision loss. The goal is to see if the drug can help preserve the pancreas's ability to make insulin and to check its safety over up to 4 year…
Phase 2 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC